Intravesical Therapies in Non-muscle Invasive Bladder Tumors
Journal Title: Üroonkoloji Bülteni - Year 2019, Vol 18, Issue 1
Abstract
In the European Association of Urology (EAU) 2015 Guidelines for non-muscle invasive bladder tumors, maintenance Bacillus Calmette-Guérin (BCG) therapy is a grade A recommendation. In the intermediate-risk group, re-evaluation is recommended after 1-year full-dose treatment; in the highrisk group, full-dose BCG is recommended for 1-3 years. Intravesical BCG therapy fails in 40% patients in an average of 2 years. In these cases, there is no alternative treatment that is considered effective. In patients with failed BCG, comparison of BCG and gemcitabine showed less recurrence in the long term with gemcitabine while progression and toxicity were similar. Early radical cystectomy should be considered in non-muscle invasive bladder cancer patients with BCG-refractory T1G3 who have good performance status and low comorbidity. In T1 tumors, invade deeper than 3 mm and/or larger than 6 mm in diameter has been associated with a 100% progression rate. BCG decreased recurrence more significantly in high-risk Ta and T1 tumors. In terms of progression of high-risk superficial bladder cancer, comparison of mitomycin C and BCG showed that BCG is superior if maintenance therapy is given. EAU guidelines recommend early bladder chemotherapy instillation (EBCI), in the low-to-intermediate risk group. There was no clear effect of EBCI in the intermediate- and high-risk group. EBCI alone reduces recurrence only in the low-risk group. However, adjuvant intravesical chemotherapy (AIVC) is recommended in the intermediate- and high-risk groups because it improves relapse-free survival. BCG and maintenance BCG therapy were found to be more effective than AIVC in reducing progression and preventing recurrence.
Authors and Affiliations
Serdar Geyik
Keywords
Related Articles
- EP ID EP550869
- DOI 10.4274/uob.galenos.2018.1116
- Views 112
- Downloads 0
Initial Outcomes and Assessment of the Transperineal Multiparametric-Magnetic Resonance Imaging/Ultrasonography Fusion Biopsy Method in Diagnosing Clinically-significant Prostate Cancer
Objective: In this study, it was aimed to investigate the success of transperineal multiparametric magnetic resonance imaging (mp-MRI)/transrectal ultrasonography (USG) fusion prostate biopsy method in prostate cancer di...
Which Patients Should Undergo Immediate or Deferred Cystectomy in Non-Muscle Invazive Bladder Cancer? Evaluation of Selection Criteria
Bladder cancer is the most common malignancy of the urinary tract in Europe. 70% of all muscle invasive is bladder cancer (MIBC) at the time of diagnosis whereas remaining 30% is non-muscle invasive bladder cancer (NMIBC...
The Effect of Framingham Score on the Oncological Outcomes in Localized (T1-T2 Stage) Renal Cell Carcinoma Patients
Objective: To evaluate the effect of cardiovascular disease risk on local recurrence, distant metastasis development and cancer-specific survival in patients with localized (stage 1 and 2) renal cell carcinoma (RCC). Mat...
Should We Perform Thoracic Imaging for Every Patient with a Renal Mass?
Objective: Current guidelines for the management of renal mass recommend thoracic imaging for potential metastatic nodules. Small size of the renal mass can be associated with low metastatic potential, which might questi...
Sentinel Lymph Node Biopsy in Lymphadenectomy for Prostate Cancer
Performing the sentinel lymph node (SLN) biopsy during prostate cancer staging aims to provide more accurate nodal staging with low complications than pelvic lymph node dissection. SLN might be found outside the extended...